Biotech Values

[rwwine]

"I now think that drug supply is an issue for GENR. There is no other plausible explanation for such a long delay from the FDA’s acceptance of the IND until the commencement of all the phase-2 trials.'

Dew...I think you had it right the first time. It is my belief that GENR management may be delaying this third study with Visudyne until enrollment is completed in the very important monotherapy study.

Last week, a friend of mine here in Milwaukee contacted the PI in Madison WI to determine if he was a qualified candidate for the study. Unfortunately he has the "dry" version of AMD and was told that this study for the “wet” version only. He was told to contact them periodically for other studies. The reason why I mention this is becuase it may confirm that enrollment for this critical "monotherapy" study is not yet complete. Upon completion, we should then see the announcement of the Phase-2 Squalamine study with Visydyne.

Keep the faith.

Regards